Abstract:Circulation Research, Ahead of Print. BACKGROUND:Cardiac hypertrophy is an adaptive response to pressure overload aimed at maintaining cardiac function. However, prolonged hypertrophy significantly increases the risk of maladaptive cardiac remodeling and heart failure. Recent studies have implicated long noncoding RNAs in cardiac hypertrophy and cardiomyopathy, but their significance and mechanism(s) of action are not well understood.METHODS:We measuredlincRNA-p21RNA and H3K27ac levels in the hearts of dilated cardiomyopathy patients. We assessed the functional role oflincRNA-p21in basal and surgical pressure-overload conditions using loss-of-function mice. Genome-wide transcriptome analysis revealed dysregulated genes and pathways. We labeled proteins in proximity to full-lengthlincRNA-p21using a novel BioID2-based system. We immunoprecipitatedlincRNA-p21-interacting proteins and performed cell fractionation, ChIP-seq (chromatin immunoprecipitation followed by sequencing), and co-immunoprecipitation to investigate molecular interactions and underlying mechanisms. We used GapmeR antisense oligonucleotides to evaluate the therapeutic potential oflincRNA-p21inhibition in cardiac hypertrophy and associated heart failure.RESULTS:lincRNA-p21was induced in mice and humans with cardiomyopathy. Global and cardiac-specificlincRNA-p21knockout significantly suppressed pressure overload-induced ventricular wall thickening, stress marker elevation, and deterioration of cardiac function. Genome-wide transcriptome analysis and transcriptional network analysis revealed thatlincRNA-p21actsin transto stimulate the NFAT/MEF2 pathway. Mechanistically,lincRNA-p21is bound to the scaffold protein KAP1.lincRNA-p21cardiac-specific knockout suppressed stress-induced nuclear accumulation of KAP1, and KAP1 knockdown attenuated cardiac hypertrophy and NFAT activation. KAP1 positively regulates pathological hypertrophy by physically interacting with NFATC4 to promote the overactive status of NFAT/MEF2 signaling. GapmeR antisense oligonucleotide depletion oflincRNA-p21similarly inhibited cardiac hypertrophy and adverse remodeling, highlighting the therapeutic potential of inhibitinglincRNA-p21.CONCLUSIONS:These findings advance our understanding of the functional significance of stress-induced long noncoding RNA in cardiac hypertrophy and demonstrate the potential oflincRNA-p21as a novel therapeutic target for cardiac hypertrophy and subsequent heart failure.

Inhibition of long noncoding RNA Gm41724 alleviates pressure overload-induced cardiac fibrosis by regulating lamina-associated polypeptide 2α

Retard or Exacerbate: Role of Long Non-Coding RNA Growth Arrest-Specific 5 in the Fibrosis

Inhibition of Prostaglandin E2 Receptor 4 by Lnc000908 to Promote the Endothelial‐mesenchymal Transition Participation in Cardiac Remodelling

Identification of a long noncoding RNA Gm17501 as a novel negative regulator of cardiac hypertrophy

Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy

The long noncoding RNA THBS1-AS1 promotes cardiac fibroblast activation in cardiac fibrosis by regulating TGFBR1

SAIL: a new conserved anti-fibrotic lncRNA in the heart

LncRNA CFRL aggravates cardiac fibrosis by modulating both miR-3113-5p/CTGF and miR-3473d/FN1 axis

Long non-coding RNA Linc00092 inhibits cardiac fibroblast activation by altering glycolysis in an ERK-dependent manner

Low-density lipoprotein receptor-related protein 6 regulates cardiomyocyte-derived paracrine signaling to ameliorate cardiac fibrosis

LncRNA FAF Inhibits Fibrosis Induced by Angiotensinogen II Via the TGFβ1-P-Smad2/3 Signalling by Targeting FGF9 in Cardiac Fibroblasts

Long noncoding RNA MALAT1 as a ceRNA drives mouse fibroblast activation via the miR-335-3p/P2ry2 axis

Downregulation of B4GALT5 attenuates cardiac fibrosis through Lumican and Akt/GSK-3β/β-catenin pathway

Cartilage intermediate layer protein-1 alleviates pressure overload-induced cardiac fibrosis via interfering TGF-β1 signaling

Abstract 230: Cartilage Intermediate Layer Protein-1 Attenuates Pressure Overload-induced Cardiac Fibrosis by Targeting Transforming Growth Factor-β1

Epigenetic signatures in cardiac fibrosis: Focusing on noncoding RNA regulators as the gatekeepers of cardiac fibroblast identity

Therapeutic silencing of lncRNA RMST alleviates cardiac fibrosis and improves heart function after myocardial infarction in mice and swine

LTBP2 Knockdown Ameliorates Cardiac Fibrosis and Apoptosis via Attenuating NF‐κB Signaling Pathway and Oxidative Stress in Mice with Cardiac Hypertrophy

Long noncoding RNA <i>Cfast</i> regulates cardiac fibrosis

lncRNA Gm20257 alleviates pathological cardiac hypertrophy by modulating the PGC-1α-mitochondrial complex IV axis

Fibroblast-localized lncRNA CFIRL promotes cardiac fibrosis and dysfunction in dilated cardiomyopathy